The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Alopecia refers to hair loss and can affect the scalp, eyebrows, eyelashes, and other areas of the body. There are different types of alopecia including an | Immunology ...

Women also report feeling lower self-esteem and greater anxiety and depression after starting to lose their hair. Counseling can help if your hair loss affects your mental health.

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

HCW Biologics shares are trading higher on Monday after the company announced clearance from the Food and Drug Administration ...

The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

This trial is a milestone for our Company, and the beginning of clinical development of treatments for quality-of-life indications. While not life-threatening, alopecia areata has no cure. Existing ...